FOXO1 forkhead domain mutants in B-cell lymphoma lack transcriptional activity.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
25 01 2022
Historique:
received: 24 09 2021
accepted: 11 01 2022
entrez: 26 1 2022
pubmed: 27 1 2022
medline: 5 3 2022
Statut: epublish

Résumé

Somatic point mutations of the FOXO1 transcription factor were reported in non-Hodgkin lymphoma including diffuse large B-cell lymphoma, follicular lymphoma and Burkitt lymphoma. These alterations were associated with a poor prognosis and resistance to therapy. Nearly all amino acid substitutions are localized in two major clusters, affecting either the N-terminal region (Nt mutations) or the forkhead DNA-binding domain (DBD mutations). While recent studies have focused on Nt mutations, we characterized FOXO1 DBD mutants. We analyzed their transcriptional activity, DNA binding, phosphorylation and protein-protein interaction. The majority of DBD mutants showed a decrease in activity and DNA binding, while preserving AKT phosphorylation and interaction with the cytoplasmic ATG7 protein. In addition, we investigated the importance of conserved residues of the α-helix 3 of the DBD. Amino acids I213, R214, H215 and L217 appeared to be crucial for FOXO1 activity. Our data underlined the key role of multiple amino-acid residues of the forkhead domain in FOXO1 transcriptional activity and revealed a new type of FOXO1 loss-of-function mutations in B-cell lymphoma.

Identifiants

pubmed: 35079069
doi: 10.1038/s41598-022-05334-4
pii: 10.1038/s41598-022-05334-4
pmc: PMC8789783
doi:

Substances chimiques

Amino Acids 0
FOXO1 protein, human 0
Forkhead Box Protein O1 0
DNA 9007-49-2
Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1309

Subventions

Organisme : Fonds De La Recherche Scientifique - FNRS
ID : FC29845
Organisme : Actions de recherche Concertées
ID : ARC16/21-073

Informations de copyright

© 2022. The Author(s).

Références

Immunity. 2015 Dec 15;43(6):1064-74
pubmed: 26620759
Nat Immunol. 2008 Dec;9(12):1388-98
pubmed: 18978794
Structure. 2008 Sep 10;16(9):1407-16
pubmed: 18786403
Cancers (Basel). 2019 Sep 25;11(10):
pubmed: 31557894
Cell. 1999 Mar 19;96(6):857-68
pubmed: 10102273
Biochim Biophys Acta. 2011 Nov;1813(11):1946-53
pubmed: 21146564
Cancer Res. 2018 May 1;78(9):2356-2369
pubmed: 29440168
Blood Adv. 2019 Jul 23;3(14):2118-2127
pubmed: 31300419
Blood Cancer J. 2015 Aug 28;5:e346
pubmed: 26314988
Oncoimmunology. 2018 Jan 25;7(5):e1423183
pubmed: 29721381
J Biol Chem. 1999 Jun 11;274(24):16741-6
pubmed: 10358014
Cell Rep. 2014 Jan 16;6(1):130-40
pubmed: 24388756
Blood. 2013 May 2;121(18):3666-74
pubmed: 23460611
Clin Cancer Res. 2016 May 1;22(9):2290-300
pubmed: 26647218
Immunity. 2021 Aug 10;54(8):1807-1824.e14
pubmed: 34380064
J Biol Chem. 2009 Apr 17;284(16):10334-42
pubmed: 19244250
Cell Mol Life Sci. 2016 Mar;73(6):1159-72
pubmed: 26686861
Blood. 2018 Dec 20;132(25):2670-2683
pubmed: 30333121
J Struct Biol. 2017 Apr;198(1):54-64
pubmed: 28223045
Cell. 2011 Sep 2;146(5):697-708
pubmed: 21884932
Nature. 2011 Jul 27;476(7360):298-303
pubmed: 21796119
Biochem J. 2014 May 15;460(1):25-34
pubmed: 24762137
Exp Hematol. 2019 Nov;79:35-46.e1
pubmed: 31669559
J Cell Mol Med. 2015 Jan;19(1):239-48
pubmed: 25292412
Nature. 2012 Oct 4;490(7418):116-20
pubmed: 22885699
Nat Cell Biol. 2010 Jul;12(7):665-75
pubmed: 20543840
Mol Cell Biol. 1996 Sep;16(9):4710-6
pubmed: 8756628
Blood. 2012 Apr 12;119(15):3503-11
pubmed: 22343918

Auteurs

Ariane Sablon (A)

Experimental Medicine Unit, De Duve Institute, Université Catholique de Louvain, Avenue Hippocrate 75, B1.74.05, 1200, Brussels, Belgium.

Emeline Bollaert (E)

Experimental Medicine Unit, De Duve Institute, Université Catholique de Louvain, Avenue Hippocrate 75, B1.74.05, 1200, Brussels, Belgium.

Constance Pirson (C)

Experimental Medicine Unit, De Duve Institute, Université Catholique de Louvain, Avenue Hippocrate 75, B1.74.05, 1200, Brussels, Belgium.

Amélie I Velghe (AI)

Experimental Medicine Unit, De Duve Institute, Université Catholique de Louvain, Avenue Hippocrate 75, B1.74.05, 1200, Brussels, Belgium.

Jean-Baptiste Demoulin (JB)

Experimental Medicine Unit, De Duve Institute, Université Catholique de Louvain, Avenue Hippocrate 75, B1.74.05, 1200, Brussels, Belgium. jb.demoulin@uclouvain.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH